AR094299A1 - Derivados de ftalazin-1(2h)-ona sustituidos - Google Patents
Derivados de ftalazin-1(2h)-ona sustituidosInfo
- Publication number
- AR094299A1 AR094299A1 ARP130105054A ARP130105054A AR094299A1 AR 094299 A1 AR094299 A1 AR 094299A1 AR P130105054 A ARP130105054 A AR P130105054A AR P130105054 A ARP130105054 A AR P130105054A AR 094299 A1 AR094299 A1 AR 094299A1
- Authority
- AR
- Argentina
- Prior art keywords
- cycloalkyl
- alkyl
- heterocyclyl
- groups
- independently selected
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
- C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Abstract
Reivindicación 1: Compuesto que tiene la estructura de fórmula general (1) caracterizado porque: en donde A y B están seleccionados independientemente entre hidrógeno, alquilo, o conectados junto con los átomos de carbono para formar un grupo cicloalquilo, heterociclilo, arilo o heteroarilo; R¹, cada vez que aparece, se selecciona independientemente entre H, halógeno, o los grupos seleccionados entre alquilo C₁₋₁₂, haloalquilo, cicloalquilo, alquiltio o el grupo alquilo (OSO₂), en donde cada uno de estos grupos está opcionalmente sustituido, además, por sustituyentes adecuados; m = 1 - 4; L= -O, -S, -NH; R² se selecciona entre los grupos sustituyentes que consisten en átomo de hidrógeno, hidroxilo, alquilo, cicloalquilo, oxo, C(O)OR⁵, -C(O)R⁵, o -C(O)NR⁶R⁷, en donde dichos grupos alquilo y cicloalquilo están sustituidos, además, por uno o más sustituyentes seleccionados entre los grupos halógeno, hidroxilo, alquilo o alcoxi; R³ y R⁴ están independientemente seleccionados, cada uno, entre átomo de hidrógeno, alquilo, hidroxilo, alcoxi, cicloalquilo, -C(O)OR⁵, -OC(O)R⁵, -O(CH₂)ₚC(O)OR⁵, -C(O)R⁵, -NHC(O)R⁵, -NR⁶R⁷, -OC(O)NR⁶R⁷ o -C(O)NR⁶R⁷ o, en forma alternativa, R³ y R⁴ forman, juntos, un grupo oxo; cada uno de los átomos D y E en el anillo está independientemente seleccionado entre átomos C o N; D y E están conectados entre sí para formar el anillo X de 5 miembros, en donde X se selecciona entre cicloalquilo, heterociclilo, heteroarilo; en donde el cicloalquilo, heterociclilo, heteroarilo están sustituidos adicionalmente con uno o más sustituyentes adecuados; R⁵, cada vez que aparece, se selecciona independientemente entre átomo de hidrógeno, grupos opcionalmente sustituidos seleccionados entre grupos alquilo, cicloalquilo, heterociclilo, arilo o heteroarilo; cada uno de R⁶ ó R⁷, cada vez que aparece, se selecciona independientemente entre H, grupos opcionalmente sustituidos seleccionados entre átomo de hidrógeno, alquilo, cicloalquilo, heterociclilo, arilo o heteroarilo; en forma alternativa, R⁶ y R⁷ se unen junto con átomo de nitrógeno para formar u anillo heterociclilo; en donde dicho anillo heterociclilo contiene uno o más heteroátomos seleccionados entre N, O, S(O)ₙ; n es 0, 1 ó 2; y p es 0, 1 ó 2.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN3742MU2012 | 2012-12-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR094299A1 true AR094299A1 (es) | 2015-07-22 |
Family
ID=54198806
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130105054A AR094299A1 (es) | 2012-12-31 | 2013-12-27 | Derivados de ftalazin-1(2h)-ona sustituidos |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US9598418B2 (es) |
| EP (1) | EP2938598B1 (es) |
| JP (1) | JP5930452B2 (es) |
| KR (1) | KR101652654B1 (es) |
| CN (1) | CN104918917A (es) |
| AP (1) | AP2015008439A0 (es) |
| AR (1) | AR094299A1 (es) |
| AU (1) | AU2013368842B2 (es) |
| BR (1) | BR112015012425A2 (es) |
| CA (1) | CA2890309A1 (es) |
| CL (1) | CL2015001655A1 (es) |
| CO (1) | CO7400872A2 (es) |
| DK (1) | DK2938598T3 (es) |
| EA (1) | EA201591239A1 (es) |
| ES (1) | ES2614885T3 (es) |
| GE (1) | GEP201706691B (es) |
| HK (1) | HK1210466A1 (es) |
| HR (1) | HRP20170219T1 (es) |
| HU (1) | HUE030613T2 (es) |
| IL (1) | IL238714A0 (es) |
| MA (1) | MA38080A1 (es) |
| MX (1) | MX2015006780A (es) |
| NZ (1) | NZ708255A (es) |
| PH (1) | PH12015501199B1 (es) |
| PL (1) | PL2938598T3 (es) |
| PT (1) | PT2938598T (es) |
| SG (1) | SG11201503670YA (es) |
| TW (1) | TWI553005B (es) |
| WO (1) | WO2014102817A1 (es) |
| ZA (1) | ZA201503218B (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR095079A1 (es) | 2013-03-12 | 2015-09-16 | Hoffmann La Roche | Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo |
| MY187449A (en) | 2013-11-26 | 2021-09-22 | Hoffmann La Roche | New octahydro-cyclobuta [1,2-c;3,4-c']dipyrrol-2-yl |
| HUE046820T2 (hu) | 2014-03-26 | 2020-03-30 | Hoffmann La Roche | Biciklusos vegyületek autotaxin (ATX) és lizofoszfatidsav (LPA) termelésgátlókként |
| EP3298005B1 (en) | 2015-05-21 | 2024-01-24 | The Regents of The University of California | Anti-cancer compounds |
| CR20180058A (es) | 2015-09-04 | 2018-02-26 | Hoffmann La Roche | Nuevos derivados de fenoximetilo |
| CN107922415B (zh) * | 2015-09-24 | 2022-04-15 | 豪夫迈·罗氏有限公司 | 新的作为双重atx/ca抑制剂的二环化合物 |
| KR20180054830A (ko) | 2015-09-24 | 2018-05-24 | 에프. 호프만-라 로슈 아게 | 오토탁신(atx) 억제제로서의 이환형 화합물 |
| MX2018001890A (es) * | 2015-09-24 | 2018-06-20 | Hoffmann La Roche | Compuestos biciclicos como inhibidores de autotaxina (atx). |
| MX2017015034A (es) | 2015-09-24 | 2018-04-13 | Hoffmann La Roche | Nuevos compuestos biciclicos como inhibidores duales de autotaxina (atx)/anhidrasa carbonica (ca). |
| CN107428762B (zh) * | 2015-10-30 | 2020-03-10 | 四川科伦博泰生物医药股份有限公司 | 酞嗪酮衍生物、其制备方法及用途 |
| WO2017101796A1 (zh) * | 2015-12-16 | 2017-06-22 | 四川科伦博泰生物医药股份有限公司 | 酞嗪酮衍生物、其制备方法及用途 |
| IL263917B (en) * | 2016-06-24 | 2022-07-01 | Univ California | Pthalazine derivatives as parp1, parp2 and/or tubulin suppressors for use in cancer therapy |
| WO2018167113A1 (en) | 2017-03-16 | 2018-09-20 | F. Hoffmann-La Roche Ag | New bicyclic compounds as atx inhibitors |
| CR20190423A (es) | 2017-03-16 | 2019-11-01 | Hoffmann La Roche | Nuevos compuestos biciclícos como inhibidores dobles de atx/ca |
| EA201992215A1 (ru) | 2017-03-20 | 2020-02-06 | Форма Терапьютикс, Инк. | Пирролопирроловые композиции в качестве активаторов пируваткиназы (pkr) |
| CN109251204A (zh) * | 2017-07-13 | 2019-01-22 | 中国药科大学 | 含有酞嗪-1(2h)-酮结构的parp抑制剂、其制法及医药用途 |
| CN108164468B (zh) * | 2018-02-09 | 2021-02-02 | 上海卫岑医药科技有限公司 | 一种parp抑制剂、其药物组合物、制备方法及应用 |
| EP3852791A4 (en) | 2018-09-19 | 2022-06-15 | Forma Therapeutics, Inc. | ACTIVATION OF PYRUVATE KINASE R |
| US20220031671A1 (en) | 2018-09-19 | 2022-02-03 | Forma Therapeutics, Inc. | Treating sickle cell disease with a pyruvate kinase r activating compound |
| CN115515939A (zh) * | 2020-05-08 | 2022-12-23 | 谛希诺生物科技有限公司 | 具有抑制外核苷酸焦磷酸酶-磷酸二酯酶的活性的新型酞嗪衍生物及它们的用途 |
| EP4304720A1 (en) * | 2021-03-11 | 2024-01-17 | Mirati Therapeutics, Inc. | Mta-cooperative prmt5 inhibitors |
| WO2023288002A1 (en) * | 2021-07-16 | 2023-01-19 | Oregon Health & Science University | Phthalazinone-based parp-1 inhibitors |
| WO2023174250A1 (en) * | 2022-03-15 | 2023-09-21 | Beigene , Ltd. | 4- (aminomethyl) -6- (1-methyl-1h-pyrazol-4-yl) isoquinolin-1 (2h) -one derivatives as mta-cooperative inhibitors of prmt5 |
| WO2024046420A1 (zh) * | 2022-08-31 | 2024-03-07 | 江苏恒瑞医药股份有限公司 | 稠合二环类化合物、其制备方法及其在医药上的应用 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6531464B1 (en) | 1999-12-07 | 2003-03-11 | Inotek Pharmaceutical Corporation | Methods for the treatment of neurodegenerative disorders using substituted phenanthridinone derivatives |
| IL155645A0 (en) | 2000-10-30 | 2003-11-23 | Kudos Pharm Ltd | Phthalazinone derivatives |
| GB2415430B (en) | 2003-03-12 | 2006-07-12 | Kudos Pharm Ltd | Phthalazinone derivatives |
| US7449464B2 (en) * | 2003-03-12 | 2008-11-11 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| JP2007517843A (ja) | 2004-01-05 | 2007-07-05 | アストラゼネカ アクチボラグ | Ｃｈｋ１阻害剤であるチオフェン誘導体 |
| JP2008510783A (ja) | 2004-08-26 | 2008-04-10 | クドス ファーマシューティカルズ リミテッド | ４−ヘテロアリールメチル置換フタラジノン誘導体 |
| US20060079510A1 (en) | 2004-09-30 | 2006-04-13 | Kristoffer Hellstrand | Use of PARP-1 inhibitors for protecting tumorcidal lymphocytes from apoptosis |
| CA2601983A1 (en) | 2005-04-06 | 2006-10-12 | Astrazeneca Ab | Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors |
| AU2006318226A1 (en) | 2005-11-25 | 2007-05-31 | Pharma Mar, S.A. Sociedad Unipersonal | Use of PARP-1 inhibitors |
| GB0610680D0 (en) * | 2006-05-31 | 2006-07-12 | Istituto Di Ricerche D Biolog | Therapeutic compounds |
| UY30639A1 (es) | 2006-10-17 | 2008-05-31 | Kudos Pharm Ltd | Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones |
| US8466150B2 (en) * | 2006-12-28 | 2013-06-18 | Abbott Laboratories | Inhibitors of poly(ADP-ribose)polymerase |
| HUE027641T2 (en) * | 2006-12-28 | 2016-11-28 | Abbvie Inc | Poly (ADP-ribose) polymerase inhibitors |
| JP2010527981A (ja) | 2007-05-25 | 2010-08-19 | アストラゼネカ・アクチエボラーグ | 癌処置用のｃｈｋ阻害剤およびｐａｒｐ阻害剤の組み合わせ剤 |
| US20090023727A1 (en) | 2007-07-05 | 2009-01-22 | Muhammad Hashim Javaid | Phthalazinone derivatives |
| RU2490265C2 (ru) * | 2007-11-15 | 2013-08-20 | Институто Ди Ричерке Ди Биолоджиа Молеколаре П. Анджелетти С.П.А. | Пиридазиноновые производные в качестве ингибиторов parp |
| UY31603A1 (es) | 2008-01-23 | 2009-08-31 | Derivados de ftalazinona | |
| CN102238945B (zh) | 2008-10-07 | 2014-10-29 | 阿斯利康(英国)有限公司 | 药物制剂514 |
| US8871765B2 (en) | 2010-07-27 | 2014-10-28 | Cadila Healthcare Limited | Substituted 4-(4-fluoro-3-(piperazine-1-carbonyl)benzyl)phthalazin-1(2H)-one derivatives as poly (ADP-ribose) polymerase-1 inhibitors |
| CN102372706A (zh) | 2010-08-09 | 2012-03-14 | 江苏恒瑞医药股份有限公司 | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 |
| CN102372716A (zh) * | 2010-08-09 | 2012-03-14 | 江苏恒瑞医药股份有限公司 | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 |
| CN102372698A (zh) * | 2010-08-10 | 2012-03-14 | 江苏恒瑞医药股份有限公司 | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 |
| US8999985B2 (en) | 2010-12-02 | 2015-04-07 | Shanghai De Novo Pharmatech Co Ltd. | Substituted phthalazin-1(2H)-ones, preparation processes and medical uses thereof |
| CN102485721B (zh) | 2010-12-03 | 2015-12-09 | 曹亚 | 取代的2,3-二氮杂萘酮化合物及其用途 |
| US20140221314A1 (en) | 2011-05-31 | 2014-08-07 | Newgen Therapeutics, Inc. | Tricyclic inhibitors of poly(adp-ribose)polymerase |
| ES2562903T3 (es) | 2011-07-13 | 2016-03-09 | Santen Pharmaceutical Co., Ltd | Nuevo compuesto que tiene actividad inhibidora de PARP |
| US20130053365A1 (en) | 2011-08-30 | 2013-02-28 | Biomarin Pharmaceutical, Inc. | Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp) |
| BR112014016163A8 (pt) | 2011-12-31 | 2017-07-04 | Beigene Ltd | piridoftalazinonas tetra ou penta-cíclicas fundidas como inibidores de parp |
| CN103242273B (zh) | 2012-02-09 | 2015-06-03 | 中国科学院上海药物研究所 | 2-芳基苯并呋喃-7-甲酰胺类化合物、其制备方法及用途 |
| KR20140121477A (ko) | 2012-02-09 | 2014-10-15 | 메르크 파텐트 게엠베하 | Ｔａｎｋ 및 ｐａｒｐ 저해체로서의 테트라히드로-퀴나졸리논 |
-
2013
- 2013-12-23 DK DK13828996.2T patent/DK2938598T3/en active
- 2013-12-23 MX MX2015006780A patent/MX2015006780A/es unknown
- 2013-12-23 SG SG11201503670YA patent/SG11201503670YA/en unknown
- 2013-12-23 PL PL13828996T patent/PL2938598T3/pl unknown
- 2013-12-23 BR BR112015012425A patent/BR112015012425A2/pt not_active IP Right Cessation
- 2013-12-23 JP JP2015550210A patent/JP5930452B2/ja not_active Expired - Fee Related
- 2013-12-23 CA CA2890309A patent/CA2890309A1/en not_active Abandoned
- 2013-12-23 EP EP13828996.2A patent/EP2938598B1/en not_active Not-in-force
- 2013-12-23 PT PT138289962T patent/PT2938598T/pt unknown
- 2013-12-23 WO PCT/IN2013/000794 patent/WO2014102817A1/en active Application Filing
- 2013-12-23 AP AP2015008439A patent/AP2015008439A0/xx unknown
- 2013-12-23 NZ NZ708255A patent/NZ708255A/en not_active IP Right Cessation
- 2013-12-23 ES ES13828996.2T patent/ES2614885T3/es active Active
- 2013-12-23 US US14/647,088 patent/US9598418B2/en not_active Expired - Fee Related
- 2013-12-23 GE GEAP201313901A patent/GEP201706691B/en unknown
- 2013-12-23 EA EA201591239A patent/EA201591239A1/ru unknown
- 2013-12-23 AU AU2013368842A patent/AU2013368842B2/en not_active Ceased
- 2013-12-23 MA MA38080A patent/MA38080A1/fr unknown
- 2013-12-23 KR KR1020157017355A patent/KR101652654B1/ko active IP Right Grant
- 2013-12-23 CN CN201380069025.0A patent/CN104918917A/zh active Pending
- 2013-12-23 HU HUE13828996A patent/HUE030613T2/en unknown
- 2013-12-26 TW TW102148473A patent/TWI553005B/zh not_active IP Right Cessation
- 2013-12-27 AR ARP130105054A patent/AR094299A1/es unknown
-
2015
- 2015-05-08 ZA ZA2015/03218A patent/ZA201503218B/en unknown
- 2015-05-10 IL IL238714A patent/IL238714A0/en not_active IP Right Cessation
- 2015-05-28 PH PH12015501199A patent/PH12015501199B1/en unknown
- 2015-06-03 CO CO15127891A patent/CO7400872A2/es unknown
- 2015-06-12 CL CL2015001655A patent/CL2015001655A1/es unknown
- 2015-11-13 HK HK15111208.8A patent/HK1210466A1/xx not_active IP Right Cessation
-
2017
- 2017-02-09 HR HRP20170219TT patent/HRP20170219T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR094299A1 (es) | Derivados de ftalazin-1(2h)-ona sustituidos | |
| AR107912A1 (es) | Inhibidores de ret | |
| AR107973A1 (es) | 6-hidroxi-4-oxo-1,4-dihidropirimidin-5-carboxamidas como agonista de apj | |
| AR100809A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR098872A1 (es) | Moduladores de tetrahidropiridopirazinas de gpr6 | |
| AR100808A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR077695A1 (es) | Derivados de pirimidina como inhibidores del factor ixa | |
| AR099379A1 (es) | Compuestos tricíclicos como agentes antineoplásicos | |
| AR094702A1 (es) | Compuestos de azabencimidazol | |
| AR095311A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante | |
| AR098912A1 (es) | Inhibidores de syk | |
| AR100807A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR088449A1 (es) | Benzilindazoles sustituidos | |
| AR090967A1 (es) | Picolinamidas macrociclicas como fungicidas | |
| AR092742A1 (es) | Piridinonas antifibroticas | |
| AR103742A1 (es) | Derivados de trifluorometilpropanamida | |
| AR095708A1 (es) | Indazoles sustituidos con diaminoheteroarilo | |
| AR100058A1 (es) | DERIVADOS DE PIRIMIDIN-PIRAZINAS FUSIONADAS MODULADORES DE RORg | |
| AR094557A1 (es) | Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con deficiencia de smn | |
| AR095359A1 (es) | Compuestos heteroaromáticos y su uso como ligandos d1 de dopamina | |
| AR092347A1 (es) | Derivados de azaindol | |
| AR091185A1 (es) | Derivados de 1,2,4-triazol | |
| AR101255A1 (es) | Derivados de isoindolinona | |
| AR099789A1 (es) | Derivados de 8-(piperazin-1-il)-1,2,3,4-tetrahidro-isoquinolina | |
| AR100439A1 (es) | Derivados de carboxamida |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |